ANDA filings
This article was originally published in The Tan Sheet
Executive Summary
FDA soon will begin posting announcements of ANDAs filed with paragraph IV certification on the Office of Generic Drugs Web site. The agency plans to list the innovator drug and dosage strength, but not the company or the date FDA received it, according to OGD Acting Director Gary Buehler. The postings may alter generic firms' filing strategies; the first ANDA for a drug product filed with a paragraph IV certification is eligible for 180-day exclusivity, and companies may choose to defer developing patent challenges for products if they are ineligible for exclusivity. ANDAs may not be posted on the Web for up to 45 days after they are listed because of FDA filing requirements